Table 3. Univariate and multivariate analyses of the prognostic influence of clinicopathological factors on recurrence-free survival.

Clinicopathological features	median RFS (month)	Univariate analyses					Multivariate analyses
		RFS (%)			χ2	P	HR	95.0% CI for HR		P
		1year	3year	5year				low	high
ECOG performance status
(0,1)	72.00	81.61	58.62	19.54	0.637	0.627
(2,3)	45.72	95.24	50.00	30.95
Age (y)
<50	72.00	83.63	63.64	27.27	3.715	0.054
≥50	44.19	87.84	50.00	20.27
Stage
II	72.00	86.89	62.30	22.95	0.532	0.466
III	72.00	85.29	50.00	23.53
Lymph nodes metastases
No	72.00	92.85	77.14	40.00	31.566	0.000	0.658	0.316	1.368	0.262
Yes	22.31	77.97	30.51	3.39
Differentiation
Well-moderate	72.00	90.32	50.00	20.97	0.002	0.961
Poor	72.00	82.09	61.19	25.37
Tumor size
≥5.7cm	32.42	80.72	39.76	13.25	16.056	0.000	1.508	0.72	3.165	0.276
<5.7cm	72.00	95.65	84.78	41.30
SCC-ag level (ng/ml)
<2	54.41	89.58	52.08	25.00	0.365	0.833
2-10	72.00	79.25	60.38	22.64
>10	72.00	92.86	53.57	21.43
Hb level (g/dl)
<10	23.25	80.00	45.71	20.00	4.283	0.038	0.879	0.504	1.531	0.647
≥10	72.00	88.30	59.57	24.47
Treatment
Radiation	52.78	90.91	54.55	29.09	0.307	0.580
Concurrent Chemoradiation	72.00	82.43	56.76	18.92
Aurora-A IHC
High	27.60	80.82	34.25	4.11	35.878	0.000	3.953	1.473	10.638	0.006
Low	72.00	92.86	83.93	48.21